Search

Your search keyword '"Simon KG"' showing total 50 results

Search Constraints

Start Over You searched for: Author "Simon KG" Remove constraint Author: "Simon KG" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
50 results on '"Simon KG"'

Search Results

1. Accounting for genetic interactions improves modeling of individual quantitative trait phenotypes in yeast

2. Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

3. Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

4. Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

5. Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

6. Response to discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: results from the Stop-NUC trial

9. Real-Life-Daten zur Sicherheit, Wirksamkeit und Lebensqualität bei HCV-Patienten, die mit Glecaprevir/Pibrentasvir behandelt wurden: Daten aus dem Deutschen Hepatitis C-Register

10. High effectiveness of elbasvir/grazoprevir (EBR/GZR) treatment in patients with HCV genotype 1a (GT1a) infection in German real-world: results from the German Hepatitis C Registry (DHC-R)

11. High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in PWID on opioid substitution therapy with HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

12. High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in a HCV genotype 1 (GT1) population with a migration background and predominant subtype 1b infection: results from the German Hepatitis C Registry (DHC-R)

14. High real-world efficacy of elbasvir/grazoprevir (EBR/GZR) in genotype 1 (GT1) infected patients with and without liver cirrhosis: results from the German Hepatitis C Registry (DHC-R)

15. Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

17. Therapie der Hepatitis C in Deutschland. Ergebnisse aus dem Deutschen Hepatitis C-Register 4 Jahre nach Zulassung der neuen direkt-antiviralen Substanzen (DAAs)

18. Entwicklung des Krankheitsbildes und der Behandlung von Patienten mit chronischer Hepatitis C-Infektion (HCV) unter Real-World Bedingungen in Deutschland: Erfahrungen aus 14 Jahren mit mehr als 16.000 Patienten

19. Langzeitnachbeobachtung nach IFN-freier Therapie bei fortgeschrittener HCV-assoziierter Leberzirrhose: Kontinuierliche Verbesserung der Leberfunktionsparameter – Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R)

21. Die Baseline HCV RNA Viruslast als Entscheidungshilfe für die Behandlungsdauer mit Ledipasvir/Sofosbuvir bei HCV Genotyp-1-Patienten: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R)

23. Entwicklung des Krankheitsbildes und der Behandlung von Patienten mit chronischer Hepatitis C-Infektion (HCV) unter Real-World Bedingungen in Deutschland: Erfahrungen aus 14 Jahren mit mehr als 16.000 Patienten

24. Sicherheit und Wirksamkeit interferonfreier antiviraler Therapien in der Behandlung fortgeschrittener HCV-assoziierter Leberzirrhose: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R)

25. Sicherheit und Wirksamkeit von direkt antiviralen Substanzen für die Therapie der chronischen Hepatitis- C -Virusinfektion vom Genotyp 4: Daten aus dem Deutschen Hepatitis C-Register (DHC-R)

26. 8-wöchige Behandlung therapienaiver Patienten mit chronischer Hepatitis-C-Virusinfektion vom Genotyp 1 mit Ledipasvir/Sofosbuvir: Daten aus dem Deutschen Hepatitis C-Register (DHC-R)

27. Sicherheit und Wirksamkeit direkt antiviraler Substanzkombinationen zur Behandlung der chronischen Hepatitis- C -Virusinfektion bei älteren Patienten (> 70 Jahre): Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R)

28. Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohort.

29. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.

30. Interpreting Cancer Survivors' Perceptions of the Survivor Label Through Social Identity and Communication Accommodation Theories.

31. Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).

32. Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C-Results from the German Hepatitis C-Registry (DHC-R).

33. Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.

34. [Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries].

35. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).

36. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.

37. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R).

38. Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?

39. Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.

40. Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.

41. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.

42. [4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)].

43. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry.

44. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.

45. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.

46. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).

47. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.

48. Effect of antiviral therapy for HCV on lipid levels.

49. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).

50. [S3 guideline hepatitis C addendum].

Catalog

Books, media, physical & digital resources